NASDAQ
IONS

Ionis Pharmaceuticals Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Ionis Pharmaceuticals Inc Stock Price

Vitals

Today's Low:
$41.26
Today's High:
$43.65
Open Price:
$41.51
52W Low:
$32.69
52W High:
$48.57
Prev. Close:
$41.29
Volume:
1250309

Company Statistics

Market Cap.:
$5.92 billion
Book Value:
2.992
Revenue TTM:
$630.59 million
Operating Margin TTM:
-74.45%
Gross Profit TTM:
$-257866000
Profit Margin:
-49.01%
Return on Assets TTM:
-10.81%
Return on Equity TTM:
-58.7%

Company Profile

Ionis Pharmaceuticals Inc had its IPO on 1991-05-17 under the ticker symbol IONS.

The company operates in the Healthcare sector and Biotechnology industry. Ionis Pharmaceuticals Inc has a staff strength of 796 employees.

Stock update

Shares of Ionis Pharmaceuticals Inc opened at $41.51 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $41.26 - $43.65, and closed at $43.51.

This is a +5.38% increase from the previous day's closing price.

A total volume of 1,250,309 shares were traded at the close of the day’s session.

In the last one week, shares of Ionis Pharmaceuticals Inc have increased by +7.43%.

Ionis Pharmaceuticals Inc's Key Ratios

Ionis Pharmaceuticals Inc has a market cap of $5.92 billion, indicating a price to book ratio of 9.1536 and a price to sales ratio of 6.1754.

In the last 12-months Ionis Pharmaceuticals Inc’s revenue was $630.59 million with a gross profit of $-257866000 and an EBITDA of $-454956000. The EBITDA ratio measures Ionis Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Ionis Pharmaceuticals Inc’s operating margin was -74.45% while its return on assets stood at -10.81% with a return of equity of -58.7%.

In Q2, Ionis Pharmaceuticals Inc’s quarterly earnings growth was a negative -43.7% while revenue growth was a positive 40.8%.

Ionis Pharmaceuticals Inc’s PE and PEG Ratio

Forward PE
90.9091
Trailing PE
0
PEG
25.7033

Its diluted EPS in the last 12-months stands at $-2.21 per share while it has a forward price to earnings multiple of 90.9091 and a PEG multiple of 25.7033. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Ionis Pharmaceuticals Inc’s profitability.

Ionis Pharmaceuticals Inc stock is trading at a EV to sales ratio of 5.3493 and a EV to EBITDA ratio of 136.0582. Its price to sales ratio in the trailing 12-months stood at 6.1754.

Ionis Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$2.97 billion
Total Liabilities
$798.00 million
Operating Cash Flow
$69.52 million
Capital Expenditure
$13.07 million
Dividend Payout Ratio
0%

Ionis Pharmaceuticals Inc ended 2024 with $2.97 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $2.97 billion while shareholder equity stood at $428.00 million.

Ionis Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $798.00 million in other current liabilities, 143000.00 in common stock, $-1639238000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $424.79 million and cash and short-term investments were $2.39 billion. The company’s total short-term debt was $24,732,000 while long-term debt stood at $1.30 billion.

Ionis Pharmaceuticals Inc’s total current assets stands at $2.62 billion while long-term investments were $0 and short-term investments were $1.96 billion. Its net receivables were $28.00 million compared to accounts payable of $24.02 million and inventory worth $25.54 million.

In 2024, Ionis Pharmaceuticals Inc's operating cash flow was $69.52 million while its capital expenditure stood at $13.07 million.

Comparatively, Ionis Pharmaceuticals Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$43.51
52-Week High
$48.57
52-Week Low
$32.69
Analyst Target Price
$49.89

Ionis Pharmaceuticals Inc stock is currently trading at $43.51 per share. It touched a 52-week high of $48.57 and a 52-week low of $48.57. Analysts tracking the stock have a 12-month average target price of $49.89.

Its 50-day moving average was $40.56 and 200-day moving average was $38.73 The short ratio stood at 9.17 indicating a short percent outstanding of 0%.

Around 76.3% of the company’s stock are held by insiders while 9500.5% are held by institutions.

Frequently Asked Questions About Ionis Pharmaceuticals Inc

The stock symbol (also called stock or share ticker) of Ionis Pharmaceuticals Inc is IONS

The IPO of Ionis Pharmaceuticals Inc took place on 1991-05-17

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$4.22
-0.09
-2.09%
$97.72
-0.72
-0.73%
$229.65
-9.25
-3.87%
$114.95
-6.8
-5.59%
$15854.7
-448.6
-2.75%
$21.41
0.08
+0.38%
$20.61
0.5
+2.49%
$89.96
-0.79
-0.87%
$21.59
-1.09
-4.81%
Magnite Inc (MGNI)
$8.03
-0.04
-0.5%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops Cimdelirsen to inhibit the production of growth hormone receptor; IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. Ionis Pharmaceuticals, Inc. was incorporated in 1989 and is based in Carlsbad, California.

Address

2855 Gazelle Court, Carlsbad, CA, United States, 92010